drugset / Trial / NCT06664125

Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia

NCT06664125

Phase 2 Recruiting 50 enrolled Jemincare
RandomizedParallel-groupOpen-labelTreatment

Summary

A Phase 2a, Multicenter, Randomized, Open-label, Active Drug-controlled Trial to Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia

Timeline

Start
2024-12-30
Primary completion
2025-06-30
Completion
2025-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject JMKX003002 Unknown Oral
Comparator sevelamer Other / unclassified Oral

Indications